Chris Wolfe - Jul 27, 2021 Form 3 Insider Report for DA32 Life Science Tech Acquisition Corp. (DALS)

Role
Chief Financial Officer
Signature
/s/ Henrikki Harsu, Attorney-in-Fact
Stock symbol
DALS
Transactions as of
Jul 27, 2021
Transactions value $
$0
Form type
3
Date filed
7/27/2021, 08:08 PM
Next filing
Aug 9, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding DALS Class B Common Stock Jul 27, 2021 Class A Common Stock 144K Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person owns 143,750 shares of Class B Common Stock which are convertible into shares of Class A Common Stock as described under the heading "Description of Securities" in the Issuer's registration statement on Form S-1 (File No. 333-257679) and have no expiration date. The shares of Class B Common Stock beneficially owned by the Reporting Person include up to 18,750 shares of Class B Common Stock subject to forfeiture to the Issuer depending on the extent to which the underwriters' over-allotment option is exercised in connection with the Issuer's initial public offering of Class A Common Stock, as described in the Registration Statement.

Remarks:

See Exhibit 24.1 - Power of Attorney.